Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.68% $32.21
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 207.88 mill |
EPS: | -4.62 |
P/E: | -6.97 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 37.50 mill |
Avg Daily Volume: | 0.732 mill |
RATING 2024-04-25 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.97 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.19x |
Company: PE -6.97 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$6.43 (-80.05%) $-25.78 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 30.29 - 34.11 ( +/- 5.92%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Mottiwala Aziz | Buy | 12 938 | Common Stock |
2024-03-18 | Mottiwala Aziz | Sell | 4 766 | Common Stock |
2024-03-15 | Mottiwala Aziz | Sell | 8 148 | Restricted Stock Units |
2024-03-15 | Mottiwala Aziz | Sell | 4 790 | Restricted Stock Units |
2024-03-15 | Wahl Bryan | Buy | 12 038 | Common Stock |
INSIDER POWER |
---|
31.10 |
Last 100 transactions |
Buy: 1 038 524 | Sell: 656 594 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $32.21 (-1.68% ) |
Volume | 0.321 mill |
Avg. Vol. | 0.732 mill |
% of Avg. Vol | 43.90 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $31.39 | N/A | Active |
---|
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.